Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Mar 6:11:1384825.
doi: 10.3389/fmed.2024.1384825. eCollection 2024.

Editorial: Epidemiology and risk factors for interstitial lung diseases

Niranjan Jeganathan  1 , Tamera J Corte  2 , Paolo Spagnolo  3
Affiliations
Editorial

Editorial: Epidemiology and risk factors for interstitial lung diseases

Niranjan Jeganathan et al. Front Med (Lausanne). .
No abstract available

Keywords: environment; epidemiology; genetics; idiopathic pulmonary fibrosis; interstitial lung disease; morbidity; prevalence; trends.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Epidemiology and risk factors for interstitial lung diseases

References

    1. Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in global prevalence of interstitial lung disease. Front Med. (2021) 8:751181. 10.3389/fmed.2021.751181 - DOI - PMC - PubMed
    1. Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc. (2012) 9:120–5. 10.1513/pats.201112-055AW - DOI - PubMed
    1. Collins BF, Raghu G. Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. Eur Respir Rev. (2019) 28:190022. 10.1183/16000617.0022-2019 - DOI - PMC - PubMed
    1. Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH. Adoption of the antifibrotic medications pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. Ann Am Thorac Soc. (2021) 18:1121–8. 10.1513/AnnalsATS.202007-901OC - DOI - PubMed
    1. Lindell K, Raghu G. Palliative care for patients with pulmonary fibrosis: symptom relief is essential. Eur Respir J. (2018) 52:1802086. 10.1183/13993003.02086-2018 - DOI - PubMed

Publication types

LinkOut - more resources